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Abstract
Human atrial and ventricular contractions have distinct mechanical characteristics including speed of contraction, volume of 
blood delivered and the range of pressure generated. Notably, the ventricle expresses predominantly β-cardiac myosin while 
the atrium expresses mostly the α-isoform. In recent years exploration of the properties of pure α- & β-myosin isoforms 
have been possible in solution, in isolated myocytes and myofibrils. This allows us to consider the extent to which the atrial 
vs ventricular mechanical characteristics are defined by the myosin isoform expressed, and how the isoform properties are 
matched to their physiological roles. To do this we Outline the essential feature of atrial and ventricular contraction; Explore 
the molecular structural and functional characteristics of the two myosin isoforms; Describe the contractile behaviour of 
myocytes and myofibrils expressing a single myosin isoform; Finally we outline the outstanding problems in defining the 
differences between the atria and ventricles. This allowed us consider what features of contraction can and cannot be ascribed 
to the myosin isoforms present in the atria and ventricles.
Keywords Heart · Myosin-structure–function · Cardiomyocytes · Cardiac proteins
The human heart is an astounding machine pumping blood 
round the body to transport oxygen, heat and nutrients to 
the peripheral tissues and returning with carbon dioxide and 
other waste products. The heart needs to match the supply 
of oxygen precisely to the local needs since there is limited 
storage of oxygen in tissues. To do this, the resting heart 
beats typically about once per second with each ventricle 
delivering ~ 70–80 ml of blood at a significant, though quite 
distinct, systolic pressure into the arteries of the systemic 
and pulmonary circulation. Between beats, both systemic 
and pulmonary arterial pressures fall to lower and quite 
distinct diastolic levels. During systole, the ventricles are 
delivering blood round the lungs and body and are required 
to deliver a large volume (70–80 ml/beat ~ 4–5 l/min) of 
blood at high pressure (for the left ventricle 120 mmHg, 
which is 1.5 atmospheric pressure or 20 lb/sq in—approach-
ing the same order as car tyre pressure). During diastole, 
the ventricles relax and are refilled with the assistance of 
atrial contraction. During their contraction, the atria deliver 
a small volume of blood (~ 20–25 ml) at a modest pressure 
of well below 20 mmHg. The contraction of the two types 
of heart chambers is quite distinct with different mechanical 
constraints (see Atrial vs. ventricular chamber mechanics 
below).
Myosin is the protein that is responsible for the genera-
tion of the powerful contractions of the heart. In the healthy 
human heart, the ventricles express predominantly β-myosin 
while the atria express predominantly the α-isoform. The 
two myosin isoforms, α and β, although 91% identical in 
motor domain sequence [1], have distinct mechanical and 
biochemical properties. Here, we will consider the extent 
to which the myosin isoforms define the nature of the atrial 
vs. ventricular contraction and how the properties of the 
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myosin isoforms are optimised for the mechanical task they 
are required to do. Before doing this, it is salient to outline 
the differences in the atrial and ventricular contraction cycle.
Atrial vs. ventricular chamber mechanics
The active and passive tension and the length changes of 
atrial and ventricular cardiomyocytes (composing the mus-
cle walls of atria and ventricles) during a cardiac cycle 
Fig. 1  Left Atrial and Left Ventricular Pressure and Volume changes 
during the cardiac cycle. a Time course of the changes of Left Atrial 
(LA) Pressure (top) and Volume (bottom) during a cardiac cycle. 
The vertical dashed line indicates the time of mitral valve opening. 
‘a’ atrial pressure increase during atrial systole; ‘x’ atrial pressure 
decrease during the rapid ejection phase of LV systole; ‘v’ atrial 
pressure increase during the slow ejection phase and the isovolumic 
relaxation of the LV; ‘y’ atrial pressure decrease following mitral 
valve opening. The figure is based on those in Stefanadis et al., Rosca 
et  al., and Pironet et  al. (REF [5], [9], and [15]) b Time course of 
the changes of Left Ventricular (LV) Pressure (top) and Volume (bot-
tom) during a cardiac cycle. Vertical dashed lines indicate (from left 
to right) the time of mitral valve closure, aortic valve opening, aor-
tic valve closure, and mitral valve opening. c and d Pressure–Volume 
loops of the LA (C) and LV (D): Arrows indicate the direction of the 
P–V loop as a function of time
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determine the pressure and volume changes of the heart 
chambers responsible for the pump function of the heart. 
The typical time evolution of left atrium (LA) and left ven-
tricle (LV) pressures and volumes during a cardiac cycle are 
shown in Fig. 1a and b. When atrial and ventricular pres-
sure and volume are plotted against one another during a 
full cardiac cycle, the result is a closed curve in the pres-
sure–volume plane, called the pressure–volume (P–V) loop. 
An example of such P–V loops for LA and LV is given in 
Fig. 1c and d.
The ventricles function as intermittent pumps that drive 
blood flow through the vessels to the pulmonary and sys-
temic circulation. Both pumps develop the pressure neces-
sary to open the semilunar valves under quasi-isometric con-
ditions during the isovolumic phase of systole. A bolus of 
blood is then ejected (stroke volume) against the increasing 
pressures of the pulmonary artery and aorta, also provid-
ing some kinetic energy to the ejected blood. The duration 
of ventricular systole is around 300 ms at the normal heart 
rates of the resting body conditions. The stroke volume 
of the two ventricles is the same (70–80 ml in humans), 
while the pressure imparted by the LV to the ejected blood 
is much higher (80–120 mmHg) than that of the right ven-
tricle (10–25 mmHg). This is due to the large difference in 
the resistance to blood flow offered by the systemic and pul-
monary circulations. The area of the LV P–V loop (Fig. 1d) 
accounts for both the extent of the stroke volume and the 
amount of pressure imparted by LV to the stroke volume, 
and is a measure of the stroke work of the LV that is related 
to the oxygen consumption of the cardiac chamber. Because 
the LV stroke work represents most of the overall cardiac 
work and accounts for a great deal of the overall energy 
consumption of the heart, most research has been focused 
on trying to understand the ejection capabilities of the LV 
during systole. As a result, little attention has been paid to 
the heart chamber located upstream, namely the LA. More 
recently, the study of the heart’s diastolic behaviour, the way 
in which the heart fills, has gained interest since impaired 
filling implies impaired ejection. This direction naturally 
led researchers to focus on the LA and on the way it modu-
lates LV filling [2, 3]. Study of the LA mechanical function 
can be performed using a variety of measuring techniques, 
such as echography, angiography, computed tomography, 
magnetic resonance imaging and invasive catheterization 
[4]. The importance of the LA as a mechanical chamber 
is now well recognised. It is supposed to empty the blood 
it receives from the pulmonary veins into the LV within a 
narrow pressure range of 8–14 mmHg within a fraction of a 
second. Even a slight increase in LA pressure may result in 
pulmonary venous regurgitation and the incoming venous 
tides are reversed, which results in the so-called pulmonary 
congestion.
During a cardiac cycle, the LA performs three different 
roles, all aimed at LV filling; they are the reservoir, conduit, 
and booster pump functions [2, 5].
First, during LV systole and isovolumic relaxation, when 
the mitral valve is closed, trans-mitral flow is zero and the 
LA provides a reservoir that receives blood from the pul-
monary veins and stores energy in the form of pressure. The 
reservoir phase of the LA cycle leads to what is referred to 
as the ‘‘v’’ wave portion of the LA pressure tracing. The 
reservoir function of LA is modulated by LV contraction, 
through the descent of the LV base during LV rapid ejection 
phase (that is responsible for the ‘x’ wave in the LA pressure 
record), by the right ventricular systolic pressure transmit-
ted to the LA through the pulmonary circulation, and by LA 
mechanical properties (i.e. chamber compliance).
After the mitral valve opens, the LA behaves as a con-
duit to fill the LV. Blood is passively transferred into the 
LV through the LA via a small pressure gradient during the 
rapid filling phase of diastole and flows passively, in very 
small amounts, from the pulmonary veins into the LV dur-
ing diastasis. The conduit function, aided in the rapid filling 
phase by the increased return of blood from the pulmonary 
veins due to the “y” wave portion of the LA pressure curve, 
is modulated especially by the LV diastolic mechanical 
properties.
At the end of LV diastole, the LA actively contracts as 
a booster pump to further fill and pressurize the LV in less 
than 100 ms. The pump phase of the LA cycle leads to what 
is referred to as the ‘‘a’’ wave portion of the LA pressure 
curve. Atrial contraction is an auxotonic type of contraction 
against increasing, but always rather low, loads. LA systole 
increases the LV end-diastolic volume by 15–30% and the 
stroke volume of the next ejection by 20–30% in normal 
subjects and substantially more in the presence of impaired 
LV relaxation. Atrial booster pump function has been esti-
mated by changes in cardiac output and LV diastolic volume 
when atrial systole was either absent or improperly timed 
[6, 7], and by relative LV filling as estimated with several 
approaches (studies quoted by [8]). LA booster pump func-
tion reflects the magnitude and timing of atrial contraction 
and is modulated by LA intrinsic contractility, LV compli-
ance, LV end-diastolic pressure (atrial after-load), and by the 
degree of the venous return (atrial pre-load) [9]. Although it 
is unclear how effective the heterometric regulation of atrial 
contraction is compared with ventricular contraction (e.g. 
Korte and MacDonald 2007) [10], it has been demonstrated 
that the Frank–Starling mechanism is also operative in the 
LA [11]. LA output increases as atrial diameter increases, 
which contributes to maintaining a normal stroke volume 
[9]. Moreover, LA contractile function may decrease in 
the presence of severe LA dilation [9], though it is unclear 
whether this may occur because the declining phase of the 
length–tension relationship is reached. In fact, the peak 
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of the active force–sarcomere length relationship is likely 
shifted in heart muscle to longer sarcomere lengths than 
expected from a reduction in the overlap between thin and 
thick filaments [12]. Thus, the study of LA function can 
provide additional information, incremental to simple LA 
volume measurement.
The evaluation of the P–V curve is the most accurate and 
representative index for characterising LA mechanical func-
tion in different haemodynamic conditions [9, 13–15]. The 
P–V relationship is depicted in Fig. 1c. Arrows indicate the 
direction of the P–V loop as a function of time. The curve 
forms a double loop, giving it a particular figure-eight shape. 
The right lobe of the curve (the one at higher volumes) is the 
‘v’ loop that represents the passive properties of the atrium, 
namely the reservoir and conduit functions and corresponds 
to LA passive filling and emptying, the latter during the 
rapid LV filling phase. During diastasis, there is little change 
in the LA volume while LA pressure increases. The left lobe 
of the LA P–V curve (the one at lower volumes) is the ‘a’ 
loop, which is caused by active contraction of the atrium. It 
may be surprising that in the LA the ‘v’ loop, that is a pas-
sive volume-dependent loop, generates more pressure than 
the ‘a’ loop, which is an active pressure-dependent loop. In 
the right atrium (RA), that exhibits a qualitatively similar 
P–V loop during the cardiac cycle, pressures are in a lower 
range (2–6 mmHg) compared to LA and, at variance with 
LA, the ‘a’ loop is usually more prominent and generates 
more pressure than the ‘v’ loop. The ‘v’ wave is more promi-
nent in LA than in the RA. ‘V’ waves are passive atrial filling 
waves and are timed during ventricular systole. The LA wall 
is relatively thicker than that of the RA and is a relatively 
stiffer chamber. Apart from a relatively thinner wall, RA size 
is more than that of LA; hence, it can accommodate more 
volume raising its pressure less. The LA is decompressed 
by relatively stiff pulmonary veins with a mean pressure of 
8–10 mmHg that cannot adequately dampen the refluxing 
tides of ‘v’ waves, while the low-pressure venae cavae of the 
RA may dampen the RA ‘v’ waves more easily. Finally, the 
adjoining systemic LV adds up to the stiffness of LA filling.
As a consequence of the biphasic mechanical behaviour 
of atrial chambers during the cardiac cycle, flow through 
the mitral valve, measured by Doppler echocardiography, 
also exhibits a biphasic behaviour [16, 17]. When the mitral 
valve is completely closed, trans-mitral flow is obviously 
zero. During the first early, passive phase of ventricular fill-
ing, trans-mitral flow exhibits a peak, termed the ‘‘E wave’’. 
Then, during diastasis, when the LV is relaxed and before 
the LA contracts, the trans-mitral flow is nearly zero. Finally, 
when the LA actively contracts, trans-mitral flow peaks 
again. This second peak is called the ‘‘A wave’’.
In summary, LA twitch contraction must be very fast 
(100 ms in humans, a few tens of ms in rodents) to complete 
LV filling before the start of the much longer LV systole. LA 
systole occurs under mechanical conditions that are quite 
different from those of LV systole; LA cardiomyocytes 
rapidly shorten against the relatively low LV end-diastolic 
pressures. A very fast atrial twitch that empties the blood 
into the ventricles becomes even more important to ensure 
adequate filling at high heart rates when the time for passive 
ventricular filling is reduced. LV twitch contraction needs 
much more contractile strength and lasts much longer to 
ensure that about 60% of the LV end-diastolic volume is 
ejected against the rather high aortic pressure. Thus, to 
optimise human cardiac contraction in the LA compared 
to LV different contraction speeds, different power outputs 
and potentially different energy economies are required. As 
we will show in the following sections, expression of dif-
ferent myosin isoforms can provide some but not all of the 
features required. Additional specific properties of atrial 
tissue, mostly independent from the features of the molecu-
lar motor expressed in the cardiomyocytes, also affect the 
pump, reservoir, and conduit functions of the atria and are 
relevant to determine an efficient mechanical performance of 
the heart. Interest in the relationship between myosin motor 
kinetics and twitch dynamics is not new. In 1967, Barany 
[18] published a comparative study of different muscles from 
a broad range of species and showed that isometric twitch 
duration was correlated closely with myosin ATPase activ-
ity. These landmark findings were subsequently substantially 
confirmed [19, 20].
Myosin isoforms in the heart
There are two isoforms of myosin found in the human heart 
commonly referred to α- and β-cardiac myosin. Each myo-
sin is a hexamer made up of two heavy chains (HC) and 
four calmodulin-like light chains (LC; see Fig. 2). The α- 
and β-HCs are expressed from different genes, MHY6 and 
MHY7, respectively, and therefore the protein heavy chains 
are also known formally as MyHC-6 and MyHC-7. The 
N-terminal 90 kDa region of the heavy chain folds into a 
globular motor domain and is followed by a pair of heli-
cal IQ domains each of which associates with two LCs and 
together the IQ domains and LCs are called the neck or lever 
arm of the myosin (see Fig. 2). The IQ domains are followed 
by a short α-helical domain, S2, and a longer α-helix domain 
referred to as the tail. The S2 and the long α-helix regions 
self-associate to form a coiled coil dimer such that one 
molecule of myosin consists of two HCs and four LCs. The 
dimer of two S2 domains together with their motor domains 
is known as heavy meromyosin (HMM) while the long-tail 
dimer is light meromyosin (LMM). The LMMs of myosin 
further self-associate to form the bipolar thick filament. In 
early literature, the whole myosin isoforms identified in the 
cardiac ventricle of small mammals were referred to as the 
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V1 to V3 isoforms where V1 and V3 were α- and β-myosin, 
respectively, and V2 was a mixture of isoforms [21], dis-
cussed in more detail below.
The two LCs that associate with each myosin isoform 
also differ. As for all muscle myosins, the LCs are called 
the essential light chain (ELC or LC1) which binds nearest 
to the motor domain and the regulatory light chain (RLC or 
LC2), for review, see [20]. The RLC can be phosphorylated 
to modulate myosin motor activity [22]. The RLC, along 
with S2 and LMM, can be removed by enzymic digestion 
of myosin to leave a functional motor domain-ELC complex 
(known as sub-fragment 1 or S1 [23]) that can hydrolyse 
ATP and move actin in a motility assay. The ELC can be 
removed but leaves a very fragile myosin motor domain 
[24]. The α- and β-myosins have distinct ELC and RLC iso-
forms known as LC1a/v and LC2a/v, where a and v stand 
for atrial and ventricular, respectively. It should be noted 
that the β-myosin and its LCs (LC1v-LC2v) have the iden-
tical sequences and are expressed from the same genes in 
slow skeletal muscle fibres which are also known as Type 
1, slow skeletal muscle fibres. Each of the four light chains 
is expressed from a different gene (LC1v, LC2v, LC1a and 
LC2a from genes MYL3, MYL2, MYL4 and MYL7, respec-
tively). The two LC1s are 80.5% identical in sequence while 
the LC2s are more variable with 62.1% identity. Both are 
considerably more variable than the HCs, which are 93% 
identical. A sequence alignment of the protein chains is 
shown in Fig. 3. Although the atrial and ventricular LCs 
preferentially associate with α- and β-myosin HC, some 
swapping of LCs may occur (as discussed further below and 
in Differences between atrium and ventricle contraction in 
addition to myosin isoforms).
In the human heart, α-myosin predominates in the atria 
and β-myosin predominates in the ventricles, but the precise 
amounts of each isoform and their distribution throughout 
the walls of the two chambers are not well defined. The 
exact amounts of the minor component can vary depend-
ing upon many factors including age, gender and health 
status. These factors are much better defined in animal 
models where many more controlled experimental studies 
have been reported. However, comparisons between model 
heart systems and the human heart are complicated by the 
observation that the ratio of α- and β-myosin is distinct for 
each mammal with species size, which is linked to heart 
rate, being a major factor [25]. Smaller mammals have an 
increasing amount of the α-isoform in the ventricles of adult 
hearts. For example, the amount of α in the ventricle/atria 
is 100%/100% in mice [26], 90%/99% in rats [27–29], and 
5%/75% in humans [30–32]. In addition to the variation 
in the ratio of the two isoforms, each isoform shows sig-
nificant variations between species. These issues are dis-
cussed in relation to motility assays and myofibril studies in 
Fig. 2  Structure of myosin. a 
The blue represents the two 
myosin heavy chains which 
make up the bulk of the myosin 
molecule. The long tail or Light 
Meromyosin (LMM) is the 
C-terminal part which forms a 
coiled coil dimer. The molecule 
can be split into two proteolyti-
cally, to form LMM and Heavy 
Meromyosin (HMM), HMM 
can be further split into sub-
fragment 1 (S1)—the globular 
motor domain and S2 a short-
coiled coil dimer. Depending 
upon the site of cleavage, S1 
can include one or both of the 
small light chains (Essential 
Light Chain and Regulatory 
Light Chain) which bind to and 
stabilise the neck/lever arm. b 
Structure of human β-cardiac 
myosin homology model 
with key structural elements 
highlighted based on the bovine 
β-myosin in the post-rigor state 
(PDB: 6FSA). The central seven 
stranded β-sheet is shown in 
red. Other structural elements 
are colour-coded to match Fig. 3
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Fig. 3  Alignment of human α- and β-cardiac myosin motor domain 
and LC sequences. a The HC alignment with key areas of the struc-
ture labelled (UNIPROT code P12883 for MYH7 and P13533 for 
MYH6). Lines under parts of the sequence have the same colour 
code as in (Fig.  2). b Sequence alignment of LC1a (MYL4—UNI-
PROT code P12829) and LC1v (MYL3—UNIPROT code P08590) 
above, and the LC2a (MYL7—UNIPROT code Q01449) and LC2v 
(MYL2—UNIPROT code P10916) below. The LC1s have a sequence 
identity of 80.51% and the LC2s sequence identity of 62.05%. * indi-
cates sequences changes between the two sequences
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Isolation of α- and β-myosin and in vitro studies of the pro-
teins and Structural differences between α- and β-myosin, 
but in general, all kinetics (ATPase activity, shortening 
velocity or in vitro motility velocity and a range of mechani-
cal parameters) are faster in small mammals than in large 
mammals (see Myosin isoforms in the heart on the structural 
differences between orthologous myosins).
The complexity of isoform expression is illustrated by 
studies of the rat heart where the proportion of β-myosin 
decreases from 50% at birth to < 10% by 3 weeks of age 
[27, 33–35]. Pressure overload also increased the β isoform 
content [36–38] while exercise reduced β [35], and hemo-
dynamic stress can induce alterations in the pattern of iso-
form expression [38]. In hyperthyroid rats, the β isoform 
decreases to zero while in hypothyroid rats, β increases to 
100% [27, 28, 39–41]. Furthermore, shifts in isoform expres-
sion may also be localised to distinct regions in cardiac 
muscle. Pagani and Julian showed that the relative amounts 
of myosin isozymes in the ventricular free walls and pap-
illary muscles may not be identical within the same heart 
[34]. Subsequent studies from multiple labs demonstrated 
that the expression of the α isoform in mammalian hearts is 
more abundant in the epicardium than in the endocardium 
of the left ventricular mid-wall, demonstrating a gradient 
in myosin expression [29, 32, 39, 42, 43]. This raises the 
possibility that the changes in the expression of myosins iso-
forms reported above could be localized to specific regions 
of the heart rather than being uniform across the heart. It 
is assumed that the mixture of α and β isoforms occurs in 
individual myocytes raising the possibility that αβ-myosin 
Fig. 3  (continued)
7316 J. Walklate et al.
1 3
heterodimers can exist in some cells (discussed below). Most 
of the model systems studied to date focus on either the 
whole heart or the left ventricle. Much less is known about 
isoform changes in the atria.
The above section refers to α- and β-myosin distribution, 
but in most cases, the literature only specifies the HC. Less is 
known about the LC distribution in the atrium and ventricle. 
The isoform distribution of both LC1 and LC2, in healthy 
humans, closely follows the pattern and variability observed 
for the HCs, with LC1a and LC2a being expressed early in 
development when α-HC is expressed in both atria and ven-
tricles. Later in development as β-expression increases, then 
the ventricle LCs expression also increases [44, 45]. Patho-
logical conditions associated with congenital heart disease 
or ischemia/reperfusion are associated with re-expression 
of α-HC and atrial forms of the LCs in the ventricle and 
down-regulation of ventricular LCs [45–48]. As for the atria, 
very little is known, but upregulation of LC1v and LC2v and 
down-regulation of LC1a and LC2a, [49] have been reported 
in association with upregulation of β-HC in atrial fibrillation 
[50, 51]. Overall, the expression of the HC and related LCs 
appear then to be closely coordinated. Another distinction 
between the LCs is in N-terminal modification as LC2a is 
acetylated, while LC1a and both ventricular LC are methyl-
ated [52].
Isolation of α‑ and β‑myosin and in vitro 
studies of the proteins
Studies of the human isoforms of sarcomeric muscle myo-
sin have been limited by availability of tissue samples. This 
means that much of our understanding of the two isoforms 
has come from the study of protein isolated from model 
organisms, such as mouse, rat, rabbit, pig or bovine heart 
samples. In addition, until recently, sarcomeric myosins like 
the cardiac myosins could not be expressed in vitro. This 
is believed to be because the popular cells used to express 
proteins (bacteria, insect cells, HEK) lacked key chaperones 
essential to the correct folding of sarcomeric myosins. The 
chaperones involved remain to be fully defined [53, 54]. To 
get round this limitation, Winkleman pioneered the use of 
a mouse muscle cell line to express the motor domain of 
human myosin [53, 55]. This has since been used by several 
groups, most notably by the Spudich and Leinwand labora-
tories who have expressed the motor domain of each of the 
12 human muscle myosin isoforms, including α and β [56, 
57]. The expressed isoforms were used to complete single 
molecule mechanics and detailed biochemical analysis of 
the major human myosin isoforms together with studies of 
many disease-associated mutations [58–61]. The approach 
has now been adopted by a few other groups, but while this 
remains the best route to express sarcomeric myosin motor 
domains, the quantities of isolated protein remain modest (a 
few mg) and it is a slow and expensive process compared to 
bacterial or insect cell expression systems. More recently, 
patient-derived stem cells have been used to grow muscle 
tissue in vitro [62, 63] and myosin can be isolated from such 
samples but again in limited amounts.
The availability of pure samples of expressed human α- 
and β-myosin motor domain with just the ELC or both LCs 
and now HMM has allowed detailed studies of the biochemi-
cal and mechanical properties of the two human isoforms 
[64, 65]. Many myosin isoforms carrying mutations associ-
ated with inherited cardiac diseases have also been studied 
but will not be discussed further here (see reviews [66–68]).
In vitro studies of human α‑ and β‑myosin motor 
domains
The mechanochemical cycle
All myosins, both muscle and non-muscle, are closely 
related and all that have been studied to date have a simi-
lar actin–myosin cross-bridge cycle, illustrated in Fig. 4a. 
The basic ATPase cycle of isolated myosin motor domain is 
slow, typically 0.05 molecules of ATP.s−1 per myosin motor 
domain (i.e. kcat; for review, see [69]; note that all rates and 
rate constants quoted for the in vitro studies are at 20 °C 
unless otherwise stated). This is equivalent to the ATPase of 
a single myosin head in a relaxed muscle where interaction 
with actin is prevented. The limiting step is Pi release from 
a stable M.ADP.Pi complex. The binding of this myosin 
complex to actin accelerates Pi release more than 100-fold 
and is concomitant with what is called the power stroke —a 
re-orientation of the converter-lever arm through ~ 120° (see 
Fig. 4a). This can either generate a force of ~ 5 pN, if con-
tracting against a load (the power stroke), or in the absence 
of load generate a rapid movement of 5–10 nm at the tip of 
the lever arm (the working stroke). If the working stroke 
is completed, then ADP is rapidly released. If the working 
stroke is prevented by the load, then ADP release is inhib-
ited resulting in a lower ATPase rate under load [70–72]. 
Once ADP is released, ATP binds rapidly (cytosolic ATP 
is normally at a concentration of several mM [73]) leading 
to the opening of the large cleft between the actin-binding 
sites of myosin and actin dissociation. Once dissociated, 
the converter-lever arm goes through the recovery stroke 
accompanied by hydrolysis of ATP. This re-primes the myo-
sin motor ready for another round of actin interaction and 
force/movement generation.
The above cycle is common for all myosin studied to date, 
what differs for each isoform is the speed at which each 
cycle is completed (the ATPase rate) and the fraction of each 
cycle time the myosin spends in the different states around 
the cycle. The duty ratio (DR) is defined as the fraction of 
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the total myosin in actin-attached states in the steady-state 
cycle (= τ/T where τ, is the lifetime of the actin-attached 
states and T is the total time of each cycle of ATP hydroly-
sis). All muscle myosins are low duty ratio motors spending 
at most ~ 10% of the cycle time attached to actin. At one 
level, this appears to be an inefficient system for force gen-
eration, since steady-state force is proportional to the time-
averaged number of strongly attached myosin cross-bridges. 
But it does mean that there is a constant pool of M.ADP.
Pi-primed motors available to the muscle, i.e. at maximum 
activity once a myosin has detached from actin, it may not 
be needed again on average for another 10 ATPase cycles 
(10 × τ = T). In fact, when shortening rapidly against zero 
load, the DR may be much less than 10% and each myosin 
may contribute once (or less than once) per each heart con-
traction/relaxation cycle.
At the single molecule level, the step size of a motor 
can be measured and for all muscle myosins that have been 
examined, the step size is similar, within the precision of the 
measurement, at ~ 7–10 nm. The lever arms are all the same 
size (2 IQ domains and two LC) and the angle through which 
the lever arm swings is therefore expected to be the same, 
to give the same step size. Similarly, the force that can be 
generated in each step is similar, within the precision of the 
measurement, at 5 pN. If the step size is the same, then the 
stiffness of the head and the site of any elastic element are 
likely to be the same.
Note however, although the step size and elementary 
force generation are the same, the life time of attachment 
events does vary from isoform to isoform. If DR is constant, 
then the average number of myosin heads strongly attached 
remains the same, but for slower myosins, the cross-bridge 
remains attached for a longer time. Thus, with slow myosins, 
the ATPase is slower and the energetic cost of maintaining 
force is lower.
Fig. 4  The ATPase cycle of actin–myosin. a Actin–myosin mechano-
chemical cycle. A is actin M is myosin and T, D, Pi represent ATP, 
ADP and phosphate, respectively. Each step, i, of the cycle is labelled 
with its equilibrium constant, Ki (= k-i/k+i, the ratio of reverse, k-i, 
and forward, k+i, rate constants). Actin monomers are shown as open 
circles. The myosin is shown as two ellipses and a linear tail, with 
the light chains as green rectangles. The colour of myosin indicates 
the nature of the interaction with actin, red shades are detached 
from actin, yellow are weakly attached to actin, and blue shades are 
strongly attached force holding states. Starting from the top left blue 
A·M rigor state, ATP binds (eq const KT) induces cleft opening to 
a weakly attached state (yellow, KT*). Myosin then detached from 
actin to form M·T (KT**). The recovery stroke follows accompanied 
by ATP hydrolysis (KH) which then allows weak rebinding to actin 
(KA). The power stroke is associated with Pi release and strong bind-
ing to actin (KPi) and precedes two step ADP release, the first asso-
ciated with an additional movement of the myosin tail or lever arm 
(KD*), and then rapid ADP escape (KD) back to the rigor state. b) 
Fractional occupancies of each state in the ATPase cycle at 3 differ-
ent actin concentrations, [A] = Km, 3 Km, and 20 Km (where Km = [A] 
required for half of the maximum turnover rate  kcat) for each isoform 
and at [A] = 3  Km plus 5 pN load. Colours of the pie chart bands 
match those of (a). Note that the three dark blue states are all very 
short lived and represent < 1% of the cycle time. The % value next to 
each chart gives the % of each cycle spent as the force holding A·M·D 
state. The Figure is adapted from Johnson et al. [75]
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Differences between the cross‑bridge cycle for α‑ 
and β‑motor domains
Typically, α and β motor domains differ about two–three-
fold in the maximum actin-activated ATPase activity 
(defined as kcat [74]), and this is also true of human isoforms 
[75]. So the ATPase cycle is the same as in Fig. 4a, but an 
α-myosin completes the cycle 2–3 times faster. If this was 
the only difference, then the two motors would have similar 
mechanical characteristics, but the two differ in how much 
of the total cycle time they spend in each state in the cycle 
and this results in distinct changes in the mechanics and the 
efficiency of how the energy of ATP hydrolysis is used [75].
The ability to express pure forms of the cardiac myo-
sin motor domain allowed Deacon et al. [57] to define the 
rate and equilibrium constants for each of the steps in the 
cross-bridge cycle as shown in Fig. 4a. While the  kcat for 
the ATPase activity is three times faster for α compared to β 
isoform, this is not reflected in the individual rate constants 
round the cycle. Of the 16 rate constants in the cycle (eight 
forward and eight reverse rate constants), 11 are at least two-
fold faster for α-myosin vs β while five remain essentially 
unchanged. Surprisingly two rate constants are faster for β; 
the two rate constants for ADP rebinding to AM,  k-D and 
 k-D* (see Fig. 4a).
The values for each of the rate constants together with the 
actin dependence of the ATPase rate allowed Mijailovich 
et al. (2017) to model the complete cycle as a function of 
actin concentration and predict the occupancy of each of 
the states during steady-state ATP turnover [75, 76]. The 
results of the modelling (Fig. 4b) show how the cycle var-
ies for the two human isoforms and can predict differences 
in the mechanical performance of the two motors. At actin 
concentrations equal to the value of  Km (the actin concen-
tration required for the ATPase rate to be 50% of the maxi-
mum,  kcat/2), the cycle is dominated by the detached and 
weakly attached states of the cross-bridge (red/pink and 
yellow shades, respectively, in Fig. 4b), and these are mar-
ginally larger for the β (~ 91%) compared to the α isoform 
(93%), leaving just 9 and 7% as strongly attached states 
(blue shades), predominantly the A.M.D form. Hence, the 
duty ratio for the two motors is similar despite the three-
fold slower cycling rate for β-myosin. This is as a result 
of key steps in the attached (Pi release, ADP release) and 
detached (ATP cleavage) parts of the cycle slowing to main-
tain a balance between the two parts of the cycle. As actin 
concentration increases to 3 Km (75% of  kcat) and 20 Km 
(95% of  kcat), the detached M.D.Pi (pink) state reduces as 
does the detached M.T (red) state, while the weakly (yellow) 
and strongly attached (blue) states increase. For the β, the 
M.T state is larger because the rate of the hydrolysis step 
is significantly slower for this isoform and now contributes 
more to limiting the overall  kcat. Note that the fraction of 
strongly attached states increases by a factor of 2 for both α 
and β, maintaining a similar increase in duty ratio as actin 
concentration increases (0.1–0.19 for α and (0.073–0.14 for 
β), i.e. both duty ratios increase in parallel. Also, note that 
the effect of load on the cycle increases the force holding 
AMD state by 1.9% for α-myosin while it increases by 3.3% 
for β. The results are plotted at three different actin con-
centrations (Fig. 4b) because it is not possible to define the 
effective actin concentrations “seen” by a myosin head in a 
shortening or isometric sarcomere.
A similar duty ratio is important as this keeps the num-
ber of cross-bridges that can hold a load in the steady-state 
constant. Thus, if the force per cross-bridge is constant (see 
below), then the similar duty ratio means that myofibrils 
containing α or β will hold a similar steady-state ensem-
ble force. The small, similar duty ratio also maintains the 
large pool of detached (M.D.Pi, pink) and weakly attached 
(A-M.D.Pi, pale yellow) cross-bridges that are available to 
go through the power stroke and contribute to force genera-
tion/force holding as needed.
In addition to predicting a similar steady-state force, the 
model of the cross-bridge cycle in Fig. 4 allows several other 
parameters of the mechanical cycle to be predicted. The bio-
chemical cycle in solution is the nearest equivalent to the 
unloaded shortening muscle fibre where every myosin head 
has ready access to actin sites and in the absence of any sig-
nificant load. Under these conditions, the maximum velocity 
at which myosin will move an actin filament is given by
where  V0 is the velocity at zero load, d is the step size, τ is 
the lifetime of the strongly attached state, DR is the duty 
ratio, and the ATPase rate is that under the condition where 
velocity is measured. Assuming a step size of 5 nm, then the 
modelling predicts a  V0 of 0.45 µm  s−1 for α and 0.2 µm  s−1, 
for β-myosin. It is also then possible to estimate how much 
ATP is used per myosin head when moving actin at  V0. As 
listed in Table 1, α-myosin uses 0.35 molecules of ATP 
per myosin head for each nm moved, 2.3-fold more than 
β-myosin. Thus, α-myosin moves 2.25-fold faster than β but 
burns up more than twice as much ATP per nm moved, a 
significant difference in the economy of energy used.
The effect of load on the rate constant for ADP release 
has been estimated in single molecule assays for β-myosin 
but not for α [70, 77]. A 5 pN load slowed down ADP release 
by ~ a factor of 3 and a similar reduction in the rate of entry 
into the power stroke (coupled to Pi release) is expected. As 
there is no effect of load on the detached part of the cycle, 
the load increases the duty ratio by increasing the population 
of strongly attached cross-bridges as shown in the last row 
of Fig. 4b. There are no experimental data for effect of load 
on the α-isoform cycle. However, if the sensitivity to load 
V0 = d∕ = d.ATPase∕DR,
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of α- is assumed to be similar to that of the β-isoform, then 
effect of load on the ATPase cycle for the two isoforms can 
be compared. As shown in Table 1, a 5 pN load increased 
the fractional occupancy of the force holding AMD state to 
1.15 about half as much as that of the β isoform (1.33). The 
ATP/s usage to bear a 5 pN load was also almost 3 times 
higher for α compared to the β isoform.
In summary, the modest differences in the amino acid 
compositions (less than 9%) of the motor domains of the 
two isoforms lead to quite distinct mechanical cycles. The 
α-isoform can move in an unloaded system > two-fold faster 
than the β isoform; thus the cycle of the α-isoform is sig-
nificantly less affected by load and use > twice as much ATP 
as the β whether unloaded or holding a force close to that 
expected in an isometric contraction. In the following sec-
tions, we will show that these characteristics are shared by 
myofibrils and myocytes expressing the different isoforms. 
This will be followed by exploring how the two isoforms are 
suitable for the distinct roles in the contraction cycle of the 
atria and ventricles.
Motility assays
In vitro motility assays measure the speed at which myosin 
will translocate an actin filament over a coated, microscope 
slide coverslip [78]. The measured velocity of movement 
or sliding velocity is approximately the equivalent to the 
unloaded velocity of shortening of a muscle fibre [79]. 
Numerous studies have demonstrated that sliding velocity 
varies not only between the 2 cardiac isoforms, but also 
between different species as is also true of skeletal muscle 
isoforms [79, 80]. At 30 °C, human α-myosin has a sliding 
velocity of 2.0 μm/s, compared to β-myosin which ranges 
from 1.2–1.5 μm/s [81–83]. The measured velocity for 
β-myosin has a strong temperature dependence, with recent 
studies showing values ranging between 0.4 and 0.6 μm/s at 
25 °C [59, 60, 84]. In common model organisms, the slid-
ing velocities are different compared to human, but the ratio 
of α:β velocities remains consistent across species at about 
2.1–2.4. For example, in rabbit, α-myosin has a velocity of 
2.8–4.6 μm/s, in pig 3.8 μm/s and in mice 5.5 μm/s [80, 83, 
85, 86]. Rabbit β-myosin has a velocity of 1.1–1.8 μm/s, pig 
1.8 μm/s and mouse 2.6 μm/s [26, 80, 83, 86].
Structural differences between α‑ 
and β‑myosin
The differences in the ATPase, biochemical cycle and motil-
ity described above are due to changes in the sequence of 
the two isoforms. While there are a few crystal structures of 
β-myosin motor domain (eg PDB files 6FSA, 4P7H, 4DB1 
and 5N69), there is none of the α-isoform. However, because 
the overall sequence identity of the two isoforms is high at 
93.2% (slightly lower in the motor domain, 91%, than the 
tail, 95%), few changes in the overall fold of the protein 
are expected. For example, smooth-muscle myosin has the 
same fold with only 40% sequence identity [87]. The 91% 
identity in the motor domains translates to ~ 76 changes in 
sequence in the motor and neck domains. The locations of 
the sequence changes are illustrated in Fig. 3, which assigns 
each sequence change to the different regions of the motor 
domain. This analysis extends an earlier comparison of α and 
β sequences, completed before any myosin high-resolution 
crystal structure of myosin was available [88]. The changes 
are scattered throughout the structure, but there is a slight 
concentration of sequence changes in the two surface loops 
(Loop 1 and Loop 2) known to be hypervariable across the 
wider myosin family [89]. There are six-sequence changes 
in the 18-residue Loop 1 which is found at the entrance 
to the nucleotide pocket. This Loop is alternately spliced 
in some muscle myosins (e.g. tonic and phasic chicken, 
smooth-muscle myosins [90], scallop, striated and catch 
muscle myosin [91, 92]), to modulate the ADP affinity to 
actomyosin. Variations in the sequence of Loop 1 have been 
introduced in some easily expressible myosins to explore the 
role of the structure of the Loop (smooth muscle, myosin 
II, mammalian Myosin 1b, 1c [93–98]), but not in a cardiac 
myosin. The experimental data suggest that the flexibility of 
the loop may affect nucleotide binding in the pocket. Both α- 
and β-isoform loops contain three flexible glycine residues 
but the position of one glycine is different. A five-residue 
sequence in Loop 1 is altered from NANAN in α-myosin to 
the one residue shorter QSPG in β-myosin. The shorter loop 
in β and the introduction of a proline could make the β loop 
less flexible and hence contribute to the slower ADP release.
There are 11 changes in the 27-residue Loop 2 which 
bridges between the upper and lower parts of the 50 kDa 
Table 1  Predicted mechanical 
performance for α- and 
β-myosin based on measured 
kcat and differences in the 
biochemical cross-bridge cycle
% AMD, fractional change in AMD under load and ATP economy are all predicted at [A] = 3 Kapp
Isoform kcat  (s−1) Vel (µm  s−1) % AMD Fractional ΔAMD 
with 5 pN load
ATP economy




α 18 0.45 13.5 1.15 1.0 0.35
β 5.9 0.2 10.2 1.33 0.35 0.15
α/β 3.05 2.25 1.32 0.86 2.86 2.33
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domain of the motor. Loop 2 forms part of the actin-bind-
ing site (together with Loop 3, Loop 4, the Cardiomyopathy 
Loop and the Helix–Loop–Helix motif, H–L–H). The struc-
ture of Loop 2 is often not well defined by crystallography or 
cryo-electron microscopy [64, 99–101] suggesting that the 
loop is flexible and retains some flexibility even when bound 
to actin in the rigor complex. The net positive charge in the 
Loop is thought to be an important part of its interaction 
with the negative charge on the N-terminal region of actin 
and introducing additional charge into the Loop can increase 
the rate of binding to actin and the affinity [102]. However, 
there is little net charge change between the α- and β-Loop 
2 (5 lysines and 2 acidic side chains in each) although the 
position of the charges is slightly different. Exploring varia-
tions in Loop 2 in chicken smooth muscle and Dictyostelium 
non-muscle myosin II also indicates that Loop 2 can alter 
the  kcat of the actin-activated ATPase reaction [103, 104]. 
Risi et al. [100] compared their β-myosin Loop 2 structure 
with that of fast muscle and non-muscle myosins in which 
Loop 2 is better resolved. They speculated that loss of the 
Loop 2 interaction with actin could play a role in producing 
a slower β-myosin. However, as mentioned above, there are 
only small changes between Loop 2 in α- and β-myosin and 
the residues at about half the positions in Loop 2 of both 
α- and β-myosin vary between mammals, although changes 
in charge are rare. It is therefore difficult to assign a spe-
cific role to residues in Loop 2 without a structure of the 
α-myosin in complex with actin to compare with β-myosin. 
In addition, the rigor structure alone does not reveal much 
about the role of Loop 2 during the process of binding to 
actin.
In contrast to Loop 2, the other actin-binding loops show 
only small changes. There is a single change in Loop 3 (Q 
to P, which is likely to reduce Loop 3 flexibility), one in the 
H–L–H motif (Y to F), both in the lower 50 kDa domain, and 
one at the start of Loop 4 (Q to L). The cardiomyopathy loop 
has no changes. These changes in the actin-binding loops are 
of interest as the affinity of the motor domain is 2–five-fold 
tighter for the β-isoform in the rigor complex and ~ two-fold 
tighter in the steady-state actin-activated ATPase assay [75, 
105]. The 2–2.5-fold change in affinity for actin is unlikely 
to be attributable to the sequence differences in one of the 
loops but each loop is likely to make a partial contribution.
Loop 3, as seen in the actin.β-myosin cryo-electron 
microscopy images of Doran et al. and Risi et al. [99, 100], 
is further away from actin than seen in other skeletal mus-
cle and non-muscle rigor complexes [106–108]. Risi et al. 
note that there is little meaningful contact with actin at this 
site which then questions if Loop 3 plays any role in the 
actin–myosin interface for β-myosin. But the Loop was only 
partially resolved in the Risi et al. structure allowing for 
some flexibility of Loop 3. It remains unresolved if Loop 3 
could make contact with actin in other stages of the cross-
bridge cycle.
There are 7 changes in the first 34 residues at the N-ter-
minus and a further 8 in the following 45-residue SH-3-like 
domain (residues 35–80). Both regions show significant var-
iation amongst both paralogues and orthologues of muscle 
myosin IIs. The role of this region in the mechanochemical 
cycle has been of interest recently because of the studies 
of the N-terminal region in non-muscle myosins 1b and 1c 
(which have no SH3 domain), indicating that this region 
modulates the strain sensitivity of ADP release [70]. Simi-
larly, studies of Drosophila muscle myosin have explored the 
34 residues following the SH3 domain because it is coded by 
exon 3, one of four alternately coded exons in the myosin II 
gene, which in combination, generate all Drosophila muscle 
myosin isoforms and can tune the power output of the mus-
cle [109–111]. Exon 3 codes for a region (residues 69–113) 
that starts at the last two β-strands of the SH3 domain and 
includes a 32-amino-acid loop that joins the SH3 to the 
beginning of the 1st β-strand of the central β-sheet. This 
region has direct interactions with the purine-binding loop 
(residues 127–135) on one side and the N-terminal helix 
(21–30; highlighted in the myosin 1b and 1c study men-
tioned above). There are also interactions with the ELC on 
the other side providing what could form a network link-
ing the position of the lever arm and the nucleotide-binding 
pocket. There are four sequence changes in the exon 3 region 
following the SH3 domain. These are mostly conservative 
but they could influence the lever arm-nucleotide pocket 
communication. There is a double change NA (α) to TP (β) 
at the end of the purine-binding loop which could also form 
part of this pathway.
In the long sequence between residues 136 and 294, there 
is only a single-sequence change (N283D) and those in the 
short Loop 1 discussed above. Following residue 294, the 
region encompassing 294–325 is another region that is alter-
nately spliced in Drosophila muscle myosin II [110]. This 
region, coded by exon 7, has 4 sequence changes and has 
also been shown to influence ADP release from actin–myo-
sin [112]. The region (326–360) following the exon-7-coded 
region has 6 sequence changes including a group of three 
residues 348–350, NSM in β changing to AGV in α-myosin. 
This region is also referred to as the J–K loop (between 
Helices J and K) and was discussed in detail by Chintha-
lapudi et al. in relation to non-muscle myosin 2C [113]. The 
J–K loop provides a connection between Switch 1 in the 
nucleotide-binding pocket and long Helix-O, which spans 
the upper 50 kDa domain (see below) with the distal end of 
the motor domain. Introducing flexibility into the J–K loop 
of myosin 2c increased the  Vmax of the ATPase threefold, 
reduced motility fourfold and turned myosin 2c from a low 
to high duty ratio motor.
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There are 5 changes in or near the long Helix-O in the 
upper 50 kDa domain (417–460). This long helix, which 
stretches from the actin-binding site (cardiomyopathy loop) 
to the nucleotide-binding pocket (Switch 1), can link infor-
mation about the occupancy of the actin- and nucleotide-
binding sites. In crystal structures, this helix, along with the 
major part of the upper 50 kDa domain, appears to move to 
open and close the major cleft as Switch 1 opens and closes 
onto the gamma Pi of ATP.
There are no changes following the end of Helix-O (resi-
due 447) until the start of the H–L–H motif (528). There are 
6 changes in a region (550–585) that encompasses the part 
of the H–L–H motif (528–559) and Loop 3 (567–577) both 
part of the actin-binding site discussed above. Between Loop 
3 and Loop 2, there is a region 580–620 with six-sequence 
changes.
Finally, the whole of the region from after Loop 2 (650) to 
the end of the converter (790), there are only 5 changes: one 
just before (S666T), and two just after (T680R and S682A) 
the third central β-strand, with two more in the converter 
region (A730V and A744T).
To reiterate, the 76 changes are scattered throughout the 
motor domain but are concentrated in certain areas. Some 
of these areas have been subject to detailed study in other 
myosins, but we are not approaching a complete understand-
ing of the role of each region of the motor in defining motor 
function. The more myosins we can study at a structural 
and functional level, the better we will understand the allos-
teric communication pathways that allow myosin function 
to be tuned for different biological roles. Not every sequence 
change between the α- and β-isoform will be tightly coupled 
to motor function. Some may be required for stability, some 
to adapt assembly for specific contexts. To understand the 
significance, if any, of each of these sequence changes for 
myosin function will require extensive molecular dynamic 
simulations of this large motor domain. This is not a trivial 
task for such a large protein although advances in comput-
ing power now make such an approach feasible [114–116].
Comparison of human α‑ and β‑myosin sequence 
changes with those in orthologous β‑myosin 
sequences
A study of many different orthologous myosins is an alter-
native route to explore structure–function relationships in 
myosin. It is known that the contraction velocity of mus-
cle from small animals is faster than that of large animals 
expressing the same myosin isoform [79]. A study of the 
isolated myosins from different mammals confirmed that this 
relationship between size and velocity in motility assays is 
a property of the myosin isoforms expressed [79]. Johnson 
et al. [117] argued that a study of the sequences of β-myosins 
from a large number of mammals may help identify which 
regions in β-myosin are tuned to adjust the velocity of con-
traction. From 67 β-myosin sequences (from mouse and bats 
to elephants and whales), they identified 56 sites which var-
ied in more than 10% of the species examined. In the major-
ity of cases, only two different amino acid residues were 
found at each location. From these 56 sites, they identified 
15 sites that had a significant association with species size 
(p < 0.01) and therefore velocity. A comparison of the sites 
associated with velocity within β-myosins, and those that 
differ between human α and β may be informative.
Johnson et al. [117] replaced 12 of the 15 sites in human β 
with the equivalent sequence for the rat β-myosin to produce 
a chimeric myosin. They found the velocity of the chimeric 
myosin in a motility assay was similar to the faster rat, and 
the ADP release from actin–myosin was also two-fold faster.
Table 2a lists the 15 sites identified by Johnson et al. At 
each of the 15 sites, the residue differs between large and 
small mammals, and in each case (except one, I421), human 
β has the residue expected for a large slower contracting 
mammal. In contrast, at these same positions, α-human 
myosin has the same residue as human β at 5 positions, but 
the residue associated with small faster mammals at 8 sites. 
At two sites, the residue in the α-isoforms does not match 
any of those in the β-isoforms (V349, Y421). Therefore, 
there appears to be an unexpected similarity between human 
α-myosin sequence and the sequence of β-myosin favoured 
by small faster mammals.
A similar analysis of sites that do not have a strong asso-
ciation with mammal size (p > 0.05) is shown in Table 2b. 
Here, the residues in the hypervariable Loops 1 and 2 have 
been excluded from the analysis as these vary in both length 
and sequence, leaving 17 sites that differ between large and 
small mammals’ β-myosin motor domains. Eight of the 
17 sites in human α-myosin differ from human β, but are 
the same as the smaller mammals. Five sites are the same 
as in both human β and small mammals. Again in human 
α-myosin, there is a preference for the sequence found in 
small faster mammals.
It is of interest to note that the regions of β-myosin tar-
geted for sequence changes among species are similar to 
those that differ between α- and β-myosin, i.e. the N-termi-
nus, the region coded by exons 3 and 7 in Drosophila, Helix-
O, the actin-binding Loops-3 and -4 and the H–L–H motif. 
To date, there has been no similar analysis of large and small 
α-myosin sequences, but there is considerably less variation 
of sequence with mammal size for α-myosin making any 
such analysis more difficult. There are also few controlled 
studies of the maximum velocity of contraction/motility for 
the α-isoform in different mammals.
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Myofibrils/myocytes expressing α‑ vs 
β‑myosin
The functional correlates associated with the differential 
expression of α- and β-myosin isoforms have been indirectly 
collected over the years from muscle mechanics studies in 
intact preparations from atrial and ventricular myocardium 
from humans and animal models that, like humans, express 
the two different isoforms in the atria and ventricles [80, 
118]. Apart from the general difference in the kinetics of the 
twitch, very little can be associated with the α- and β-myosin 
function from studies of intact myocardium (see Differences 
between atrium and ventricle contraction in addition to myo-
sin isoforms). One major difference is in the maximal twitch 
force, which is lower in the atrium, mostly due to fundamen-
tal differences between atrial and ventricular myocardium 
in myofibril density and in excitation–contraction coupling 
mechanisms. Also, note the wide spectrum of other sarco-
meric protein isoforms besides the myosin motor, discussed 
in Differences between atrium and ventricle contraction in 
addition to myosin isoforms.
Attempts made to estimate α and β cross-bridge dynamics 
from intact multicellular cardiac preparations took advan-
tage of the α/β-isoform shift that had been described follow-
ing treatment with agents capable of modifying the thyroid 
state of animal models (usually, rabbit or rat; see above). 
The mechanical [27, 34, 119, 120], myothermal (rabbit [121, 
122]), and ATPase behaviors [27] of papillary muscles of 
known α- and β-myosin isoform composition were then 
compared. Note that in these earlier studies, the myosin iso-
forms were referred to as V1-α, V3-β and V2 intermediate. 
Results of these studies showed a 3–6 times faster  Vmax, 
2–3 times faster cycling rate for the α sarcomeres together 
with about half the economy of contraction compared to β 
Table 2  β-myosin sequences that vary between large and small mammals compared to the same site in human α-myosin
A) Fieen sites with a high probability of associa	on with mammal mass.
B) Remaining sites excluding the hypervariable Loop 1 and Loop 2 
β-myosins compared to human α-myosin No. of sites
≡Hum α  Hum β & in β of sm mammals 6 
≡Human α  Human β & in β of L mammals 0 
Human α ≠ Human β  but α ≡β of sm mammals 10 
Human α ≠ Human β  but α ≡β of L mammals 4
Human α differs to all β-myosin 22 
Pale grey background – sequence specific to β-myosin of small mammals, White background – 
specific to β-myosin of large mammals. Dark grey – specific to the human isoform myosin 
Site No. Hum α Hum β Sm Mam β Lrg Mam β Myosin region 
15 Y Y F Y N-terminus 
65 N Y N N SH3
326 A S A S
Exon 7 & Helix J & K 343 S S P S
349 V M I M
366 Q L Q L Loop-4 
421 Y I S A
Helix-O 
424 I T I T
430 A A S A
434 K R K R
553 Y F Y F Helix-L-Helix 
569 I I V I
Loop-3 
573 Q P Q P
580 I I V I Post Loop-3 
607 A G A G
Red leers – sequence specific to β-myosin of small mammals, Black leers – specific to β-myosin of 
large mammals. Blue leers – specific to the human isoform myosin 
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[119, 121, 122]. No difference in the average force per cross-
bridge was detected [122].
In more recent years, the functional properties of α- and 
β-myosins have been characterized in small de-membranated 
myocardial samples expressing known amounts of the two 
isoforms. The myosin isoforms expressed were varied in 
animal model systems (rat, guinea pig, rabbit) via altera-
tions in the thyroid state, while in the case of human and 
other large mammals, samples from atria and ventricles were 
compared. In these samples, the mechanics of contraction 
were studied in calcium-activated tissue strips, myocytes or 
isolated myofibrils. The various mechanical parameters that 
can be measured in these studies provide high-resolution 
tools to estimate the isoform-dependent kinetics and energet-
ics of actomyosin motors working in arrays as cross-bridges 
throughout the chemo-mechanical cycle (see Fig. 4a). By the 
simultaneous measurement of force and the ATPase activ-
ity of de-membranated cardiac preparations, the energetic 
cost of isometric tension can be estimated. According to 
the Huxley 1957 model of contraction, the energetic cost of 
tension generation is equal to the ATP consumption divided 
by force, and is directly proportional to the rate at which 
cross-bridges leave the force generating states [123, 124].
Human atrial and ventricular strips and myocytes
Results from the coupled measurement of maximal calcium-
activated isometric force production and ATP consumption 
in chemically skinned human atrial (75% α) and ventricu-
lar (100% β) strips ([125, 126] at 20 °C showed a 3 times 
larger ATPase in the atria compared to the ventricle (Fig. 5a, 
Table 3) together with no significant difference in maximal 
isometric force,  Po, after correction for myofibrillar density 
which is lower in the atria. This resulted in a 5 times lower 
tension cost of contraction (i.e. 5 times more economical 
contraction) of pure β-myosin human ventricle compared 
to mostly α human atrial sarcomere (Table 3). The differ-
ence in tension cost of contraction of α vs β sarcomeres is 
preserved also at the physiological, submaximal activation 
of the myocardium as the calcium sensitivity of force and 
ATPase activity showed no dependence on MHC isoform 
(Table 3). (There was also no change in the calcium sensi-
tivity of velocity in a motility assay between purified rabbit 
psoas vs. porcine cardiac HMM when using recombinant 
human troponin and tropomyosin [127]). Human α-myosin 
isoform also imparted 5–10 times higher speed of force 
development in atrial sarcomeres compared to the almost 
pure β-isoform of the ventricle, as quantified in skinned 
myocytes and single myofibrils isolated from human cardiac 
samples (12–15 °C, [125, 128]). Similar results (force, speed 
Fig. 5  Active tension generation and ATPase activity in human atrial 
and ventricular de-membranated strips and myofibrils. a Recordings 
of force (upper traces) and absorbance signal of the NADH-coupled 
ATPase (bottom traces) in a human atrial trabecula (left) and a left 
ventricular strip (right) during a contraction–relaxation cycle at 
saturating  Ca2+ concentration. ATP consumption was determined 
from the slope of the absorbance signal (15–20  °C); from Narolska 
et  al. REF [125]. b Recordings of force responses (upper traces) of 
atrial (right) and ventricle (left) myofibrils maximally activated and 
fully relaxed by fast solution switching (pCa changes at arrows as 
indicated (15 °C); from Piroddi et al. [128]. Fast length changes are 
applied to the myofibrils under conditions of steady tension genera-
tion as indicated by the recording of preparation length (lo). kACT  is 
the rate constant of tension generation after fast  Ca2+ activation; kTR 
is the rate constant of tension redevelopment after the release–re-
stretch. To better resolve the time course of tension activation and 
relaxation of atrial (a) and ventricular (v) myofibrils, the experimental 
recordings (bottom traces) are superimposed on a faster time base and 
after normalization for maximal tension. Full tension relaxation is 
biphasic: slow kREL is the rate constant of the early slow force decline 
estimated from the slope of the regression line fitted to the tension 
trace normalized to the entire amplitude of the tension relaxation 
transient; fast kREL, is the rate constant for the final fast phase of ten-
sion decline estimated from a mono-exponential fit
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of contraction, ATPase and calcium sensitivity) have been 
obtained in the many attempts to characterise α vs β sarco-
meric functions by studies of skinned ventricular prepara-
tions from animal models with altered α/β ratio associated 
with altered thyroid state [129–131] or different age [132]. 
Differences in the extent of the overall increase in speed 
observed in the presence of the α-isoforms were attributed 
to differences in animal species, temperature and experi-
mental approaches to mechanical measurements. Of note, 
the difference in sarcomeric functions associated with the 
presence of α- and β-HC isoforms is further tuned by the 
expression pattern of atrial and ventricle LC isoforms. This 
was initially proved to be the case in human right ventricular 
skinned strips from congenital heart disease patients (100% 
β-MHC) presenting re-expression of LC1a in adults. This 
re-expression of LC1a was associated with higher speed of 
force development and shortening as well as higher maximal 
force [46] with an overall compensative effect [44, 133]. 
These conclusions have been confirmed and extended in 
transgenic mice models showing the increase in maximum 
shortening velocity and power output of both atrial and 
ventricular skinned fibers ectopically overexpressing atrial 
forms of both LC1 LC2 [134].
Human atrial and ventricular myofibrils
Studies on isolated myofibrils from human atria and ven-
tricles, activated and relaxed by fast solution switching, 
provided further understanding of the role of α and β iso-
forms at the sarcomere level (Fig. 5b; [128, 135, 136]. In 
these experiments, in addition to the mechanical parameters 
related to force development (kTR) and redevelopment (kTR), 
it was possible to clearly resolve the biphasic kinetics of 
full calcium relaxation [137] and measure the parameters of 
both the slow and fast relaxation phase (Table 3; [138]). As 
expected, relaxation kinetics were much slower in human 
ventricular myofibrils (ca. 100% β) than in the atrial myofi-
brils (ca. 80% α). For the β-myofibrils, the linear phase of 
relaxation lasted twice as long and its rate constant, slow 
 kREL, was 3–4 times slower than in α-myofibrils [128, 137]. 
The difference in the rate constant of the fast phase was even 
larger (Table 3).
A two-fold increase in the half-time of relaxation over 
controls was also observed in 100% β rat skinned ventricu-
lar strips using caged calcium chelators [130]. In myofibril 
experiments, performed in the virtual absence of inorganic 
phosphate, slow  kREL equals the rate of cross-bridge leaving 
force generating states [138]. From the five-fold difference 
in slow  kREL, observed between human atrial and ventricular 
Table 3  Means (± SEM) of mechanical and ATPase parameters of isometrically contracting human atrial and ventricle myofibrils and skinned 
preparations
Data in parentheses are number of specimens. Data are afrom Piroddi et al. [128] and Belus et al. [31] (15 °C) and b from Narolska et al. [126] 
(15 °C for mechanical experiments and 20 °C for ATPase assays; Active tension corrected for different myofilament content of atrial and ven-
tricular specimens).  pCa50  Ca2+ concentration at which half the maximal isometric force or ATPase activity is obtained; nHill steepness of the 
pCa-force and pCa-ATPase relations. Tension cost: ratio of ATPase over isometric tension development. Mechanical parameters as defined in 
Fig. 5. + significant at p < 0.002: * significant at p < 0.001: $ + significant at p < 0.05
Human  Myofibrilsa Human skinned  muscleb
Atrial Ventricular Atrial Ventricular
β-MHC content (% of total MHC) 30 ± 5 (8) 24.6 ± 3.2 (14) 94.7 ± 5.2 (6)$
Passive tension (mN  mm−2) 6.4 ± 0.6 (76) 10.1 ± 1.1 (53)+
Active tension
 Po (mN  mm−2) 125 ± 7 (52) 108 ± 7 (53) 32.8 ± 8.5 (14) 21.1 ± 2.1 (6)
 kACT   (s−1) 3.73 ± 0.18 (54) 0.73 ± 0.03 (62)*
 kTR  (s−1) 3.55 ± 0.19 (46) 0.68 ± 0.03 (55)* 7.76 ± 1.54 (14) 0.87 ± 0.06 (6)$
Full tension relaxation
 Slow phase duration (ms) 126 ± 6 (47) 226 ± 8 (47)*
 Slow  kREL  (s−1) 0.52 ± 0.04 (47) 0.15 ± 0.02 (47)*
 Fast  kREL  (s−1) 16.0 ± 1.0 (47) 2.90 ± 0.16 (47)*
Ca2+ sensitivity of force
  pCa50 force  pCa50 force 5.61 ± 0.03 (8) 5.61 ± 0.02 (8) 5.68 ± 0.04 (14) 5.67 ± 0.04 (6)
 nHill force 2.31 ± 0.37 (8) 2.98 ± 0.25 (8) 2.70 ± 0.17 (14) 2.29 ± 0.29 (6)
Ca2+ activated ATPase (mmol  l−1  s−1) 0.260 ± 0.025(14) 0.051 ± 0.011 (6)$
Ca2+ sensitivity of ATPase  pCa50 ATPase 2.70 ± 0.17 (14) 2.29 ± 0.29 (6)
nHill ATPase 2.33 ± 0.14 (14) 2.36 ± 0.35 (6)
Tension cost (mmol  kN−1  m–1  s−1) 11.4 ± 1.4 (14) 2.4 ± 0.3 (6)$
7325Alpha and beta myosin isoforms and human atrial and ventricular contraction 
1 3
myofibrils, a five-fold increase in the rate of cross-bridges 
leaving their force generating states (associated with 
MgADP release) can be inferred for α- and β-MHC. A simi-
lar conclusion was drawn from direct measurements of the 
tension cost [125, 131]. Interestingly, sinusoidal length per-
turbation analysis of LV myocardial strips [139] suggested 
a four-fold higher rate of MgADP release (and two-fold 
higher MgATP binding) for 100% α- vs 100% β-HC con-
tent of rats and mice generated by an altered thyroid state. 
Similar results were also obtained in skinned human atrial 
myocytes [140] and myofibrils [31], from atrial fibrillation 
patients compared to sinus rhythm controls. Atrial fibrilla-
tion caused a significant increase in the relative amount of 
the slow β-HC expressed by the human atrial myocardium 
compared to control conditions (from 10–25% to 40–50%, 
[141]) which could directly account for the observed marked 
reduction in activation and relaxation kinetics observed in 
the myofibrils from atrial fibrillation patients [31], in asso-
ciation with the parallel shift of LC1 and LC2 expression 
from the ventricular to atrial forms [49, 50]. The negative 
impact of the HC isoform change on the power output and 
velocity of atrial contraction may then contribute to the atrial 
contractile dysfunction observed in atrial fibrillation, in the 
rather complex picture of alterations of gene expression 
observed in human atrial fibrillation at the proteomic and 
metabolomics levels [51].
A direct strong positive modulation of power out-
put by the HC isoform ratio was also observed from the 
force–velocity curves of skinned rat ventricular myocytes 
[10, 129, 142] showing a linear correlation between the peak 
of the power profile and the amount of α-isoform over β, up 
to about 3 times increase for the extreme conditions. Addi-
tionally, the key parameters of the force–velocity relation 
all progressively decreased with increased β-HC content. 
A decrease in the curvature of the force velocity curve for 
β-myosin compared to α (for the same load velocity slows 
proportionately more) is indicative of a change in load 
dependence of events in the cycle (i.e. ADP release) between 
the two isoforms. Moreover, the decrease in the values of 
relative force and velocity at which power output is optimal 
 (FOPT and  VOPT) with increasing β-myosin content could be 
a major cause of lower left ventricular power in β-HC heart 
as striated muscle in vivo is thought to operate at short-
ening velocities near  VOPT. The ensemble of these results 
agrees then with previous measurements in intact prepara-
tions as well as with in vitro motility and single molecule 
studies of α- and β-isoforms. Interestingly, sarcomere length 
dependence of power output was found to be greater for β- 
vs α-myosin sarcomeres [10] perhaps indicating a greater 
impact of the Frank–Starling mechanism in the human ven-
tricle vs atria.
In summary, mechanical studies of cardiac muscle/
myocytes/myofibrils expressing known amount of α- and 
β-myosin showed that the two isoforms working in sarcom-
eres develop similar maximal isometric force. The same 
is true for the isometric force developed by atrial and ven-
tricular tissue, after normalization for myofibril content. 
Mechanical studies, coupled with ATPase measurements in 
muscle strips, reported marked differences in ATPase and 
the maximal shortening velocity,  Vo, of α vs β, matching 
in vitro myosin isoform properties. Modelling of the econ-
omy of α vs β (Fig. 4 and Table 1) matches change in LA vs 
LV tension cost.
Differences in  kACT  (dominated by the Force Generation 
Event) and  kREL (dominated by CB detachment—mostly 
the ADP release step) of α vs β are indicative of isoform-
dependent differences in key steps of the CB cycle (Pi 
release, ADP release). Differences in force–velocity relation, 
still to be thoroughly assessed, make it possible to argue 
(Fig. 5 and Table 1) that the load dependent inhibitory effect 
would be larger on β vs α (V vs A), independent of any dif-
ference in motor stiffness.
Differences between atrium and ventricle 
contraction in addition to myosin isoforms
Contraction twitch amplitude and time course are profoundly 
different in atrial and ventricular myocardium. Figure 6 
shows two examples of twitches recorded from intact human 
trabeculae, dissected from the left atrium and the left ventri-
cle, respectively. Tension developed by ventricular myocar-
dium is greater (by about 30–50%) and the duration of the 
entire contraction–relaxation cycle is almost doubled in the 
ventricle compared to the atrium. These differences are only 
partly attributable to diversities in myosin isoform as clearly 
evident from force recordings in the mouse. In this species, 
ventricular and atrial myocardia express the same myosin 
isoform, i.e. > 99% α in both chambers, but ventricular con-
traction is invariably stronger and slower (e.g. see [143]). In 
atrial myocardium, the extracellular matrix is more abundant 
and therefore cell density lower. Atrial cardiomyocytes are 
smaller in volume and typically spindle-shaped (rather than 
rod shaped). Atrial cells have similar length to ventricular 
cells yet a transversal dimension that is about half of the 
ventricular ones (8–10 µm vs 18–20 µm) [144]. In parallel 
with these histological differences, crucial ultrastructure dis-
similarities have been described. First, the atria have a lower 
density of contractile material in the cytoplasm (with higher 
relative density of other structures, such as the sarcoplas-
mic reticulum or mitochondria) [144]. The lower densities 
of myocytes within the tissue and myofilaments within the 
cardiomyocytes are likely the main player for the lower ten-
sion level developed by atrial myocardium. A second major 
difference, as mentioned above, consists in the modality and 
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levels of calcium activation, which influence both contrac-
tion amplitude and time course [145].
Calcium recordings from human, large mammals and 
rodent myocardium highlight a faster time course of cal-
cium rise and decay in the atrium of all species (see e.g. 
[144–149], and Fig. 6b). Responsible for the faster calcium 
cycling in the atrium are the differences in the expression 
and function of excitation contraction coupling proteins as 
well as the different sarcolemmal and sarcoplasmic reticu-
lum (SR) ultrastructural features, including the extent of 
transverse tubules and abundancy of non-junctional SR (e.g. 
[150, 151]).
In both atrial and ventricular cardiomyocytes, the bulk of 
the  Ca2+ required for contraction is released from the SR in 
response to a small amount of  Ca2+entering the cell through 
the L-type  Ca2+ channel during the action potential [152]. 
The action potential duration (APD) and the extent of L-type 
 Ca2+ current are known to alter the amplitude and dura-
tion of the systolic  Ca2+transient [153]. The action potential 
duration is shorter in the atrium (see e.g. [144, 154]. The 
difference is subtle in small rodents, which have faster heart 
rates, but severe (up to 200 ms) in the case of human myo-
cardium (Fig. 6b).
In the atrium, the  Na+–Ca2+ exchanger (NCX) protein 
levels are lower than those seen in the ventricle (e.g. ∼50% 
less in human atrium vs ventricle [155], and cytosolic  Ca2+ 
removal is brought about mainly through  Ca2+ uptake into 
the SR by a  Ca2+-ATPase isoform, SERCA2a. Its activity is 
modulated by another protein, phospholamban (PLB), which 
plays an inhibitory role. PLB is less expressed and is cou-
pled to higher SERCA2a levels (e.g. in the atrium of rat and 
mouse the PLB to SERCA2a ratio is 4–5 times lower than 
Fig. 6  Twitch tension, intracel-
lular calcium transient and 
action potential of human atrial 
and ventricular myocardium. a 
Representative isometric twitch 
tension recordings from intact 
human atrial and ventricular 
trabeculae dissected from left 
atrial and ventricular surgery 
samples of non-failing non-
hypertrophic patients in sinus 
rhythm. b Representative action 
potentials (top) and intracellular 
calcium transient (bottom) from 
human atrial and ventricular 
cardiomyocytes isolated from 
the same surgery samples as in 
a. Ventricular traces are from 
Coppini et al. [149] Circ 2013 
(152). Atrial traces are from 
Ferrantini and colleagues col-
lected with the same experimen-
tal approach as in Coppini et al. 
[149] Circ 2013 (152)
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in the ventricle [156]). The lower PLB to SERCA2a ratio 
underlies the enhanced SERCA2a activity and faster rate of 
calcium decay of atrial myocardial preparations [143, 157].
The cardiomyocyte membrane is provided with trans-
verse tubules (t-tubules), deep membrane invaginations 
able to conduct the action potential in depth and therefore 
responsible for a synchronous activation of calcium release 
by the SR throughout the entire cell [143, 150, 158]. In the 
ventricle, particularly in rodents, the transverse tubules are 
very abundant, they are repeated with a periodicity that 
is equal to that of the sarcomeres (at the Z lines) and pro-
mote a homogeneous and synchronous calcium activation 
of the whole cell. Conversely, in atrial cells, the density 
of t-tubules is low or negligible (according to various spe-
cies) and the SR  Ca2+ stores can be therefore divided into 
junctional (j-SR), i.e. the SR regions coupled with surface 
sarcolemma or t-tubules, and the much more abundant cen-
tral non-junctional SR (nj-SR). Calcium release from nj-SR 
occurs through diffusion of calcium from neighboring areas 
[159]. This non-homogeneous calcium activation in atrial 
cells (especially at a low inotropic level) implies that myo-
filaments corresponding to nj-SR are activated at much 
lower levels and represent a source of contractile material 
that could be recruited “on demand” [143, 158]. This mech-
anism could additionally increase the inotropic reserve of 
the atria, i.e. the potential of increasing  Ca2+ transient and 
contraction amplitude in response to need. The real extent 
of the t-tubule network in atrial myocytes of large mammals 
(including humans) is still debated, though it is invariably 
lower compared to that of ventricular myocytes [160–162]. 
A significant cell-to-cell variability of t-tubule organization 
and  Ca2+ homeostasis across the atria has been also reported 
in large mammals, with the coexistence of homogenously 
(ventricular-like) activated cells and non-homogeneously 
activated ones [163]. Concerning the release phase of the 
 Ca2+ transient, there also appears to be a greater expres-
sion of inositol 1,4,5-tri-phosphate receptors (IP3R’s) in the 
atrium. In atrial myocytes, sarcolemma IP3R's activation 
is an additional pathway to trigger SR calcium release that 
significantly potentiates the RYR2-mediated calcium release 
and, if activated, results in faster calcium rise and substantial 
inotropic response. Of note, the rate adaptation of the  Ca2+ 
transient and twitch duration in response to inotropic stimuli 
(i.e. high stimulation frequency and β-adrenergic activation) 
are less pronounced in the atria because SERCA activity, the 
main agent responsible for this rate adaptation behaviour, is 
already extremely high at baseline.
Finally, differences in intracellular  Ca2+ buffering also 
play a major role in the amplitude and time course of the 
activator calcium signal e.g. [164]. In both atrial and ven-
tricular cardiomyocytes, the major ‘fast’  Ca2+ buffers are 
SERCA and the myofilament protein troponin C. Hence, dif-
ferences in the properties of these intracellular  Ca2+ buffers 
and/or their regulation, e.g. different myofilament  Ca2+ 
buffering capacity or altered affinity of SERCA for  Ca2+ 
through the action of PLB, may also result in alterations of 
the kinetics of the systolic  Ca2+ transient between atrial and 
ventricular myocytes. Though, healthy atrial and ventricular 
tissue present comparable myofilament calcium sensitivity 
(Table 3), intracellular  Ca2+buffering power is substantially 
greater (up to three times) in the atria compared to the ven-
tricles (e.g. because of higher SERCA activity but also rela-
tive mitochondrial density) and this increased  Ca2+buffering 
power can contribute to smooth the calcium transient peak.
Besides E-C coupling diversities, a number of differ-
ences in the expression of protein isoforms at the sarcomere 
level can be described in addition to the different myosin 
isoforms.
Titin transcripts are subjected to a series of differential 
splicing events in the I-band segment leading to the so-called 
N2A and N2B isoform transcripts [165]. In most species, 
small and large titin isoforms are co-expressed in widely 
varying ratios. The smaller isoform that contains the N2B 
element (N2B titin) is stiffer than the larger isoform that 
contains both the N2B and N2A elements (N2BA titin). The 
expression of small and large titin isoforms at different ratios 
is thus one means to modulate cardiac myocyte stiffness 
[166]. The more compliant N2BA titin is more expressed 
in atria and therefore expected to reduce diastolic tension 
and facilitate the reservoir function of the atria during their 
diastole (Fig. 1).
As discussed in Myofibrils/myocytes expressing α- vs 
β-myosin, the essential (LC1) and regulatory (LC2) Light 
Chains tune the function of the myosin head and poten-
tially influence its maximum force generating capacity and 
its  Ca2+-sensitivity [167–170]. Differences in LC isoforms 
and their phosphorylation levels as well as chamber-specific 
post-translational modifications of other sarcomere proteins 
(e.g. myosin binding protein C, Troponin T) are likely to 
play a role and considerably complicate the scenario of the 
mechanisms underlying the differences between atrial and 
ventricular contraction.
Outstanding problems
The super‑relaxed state of myosin, and regulation 
of the thick filament
Thus far, we have avoided mentioning the role of the thick 
filament in regulating cardiac contractility. This regula-
tory mechanism has come to prominence in recent years 
as the discovery of the so-called super-relaxed state of 
myosin (SRX); the order–disorder transition of the thick 
filament, and stretch activation mechanisms have coalesced 
into a novel mechanism for regulating the availability of 
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myosins in the thick filament for contraction (for review 
see [171–173]. As for other aspects of cardiac contraction, 
attention to date has focussed on ventricles and β-myosin, 
so little is known about these mechanisms in atria or with 
α-myosin. The general assumption is that similar mecha-
nisms will operate but there may be subtle but important 
differences between the atria and ventricles, and between 
α- and β-myosin. In a simplified overview, the two heads of 
a muscle myosin molecule have been observed, in negative 
stain electron microscopy [174] and cryo-electron micros-
copy [175, 176], to self-associate such that the actin-binding 
site of one head blocks the nucleotide pocket of the second 
head. In this conformation, the ATPase activity is < 10% 
of the normal, relaxed, switched-off or relaxed myosin in 
the absence of actin—hence, super-relaxed [177]. These 
interacting heads are then believed to pack down onto the 
thick filament to create the ordered thick filament structure 
observed by both low angle X-ray scattering and electron 
microscopy [178]. Modulation of the relaxed/SRX myosin 
and the ordered/disordered thick filaments equilibriums by 
stretching the thick filament, by  Ca2+ or by phosphoryla-
tion of either the RLC or MyBP-C may regulate contrac-
tion output by adjusting the availability of myosin heads. 
Understanding how α- and β-myosin structures may differ in 
this respect and how such modulation of myosin availability 
may differ in atria and ventricles is therefore of interest (see 
the following section on heterogeneity in myosin dimers).
Heterogeneity in the myosin content of myocytes: 
a role for α‑myosin in the ventricle of large 
mammals?
As stated above, the α-myosin accounts for 5–10% of the 
total myosin expressed in the healthy human LV (e.g. [30]). 
The functional importance of such low expression levels of 
α-myosin in the LV is unclear. Genetic studies have associ-
ated mutations in the α-myosin gene with some cases of 
hypertrophic (HCM) and dilated (DCM) cardiomyopathy 
[179], suggesting that these low levels of α-myosin may be 
involved in LV contractile function [180]. This may be espe-
cially true if α-isoforms are localized to specific regions of 
the heart. In this regard, it has been shown that the expres-
sion of α-myosin in human and pig hearts is more abundant 
in the sub-epicardium than in the sub-endocardium of the 
left ventricular free wall [42, 43, 181]. Efficient myocardial 
pump function depends on the precise coordination and tim-
ing of regional electrical and mechanical activation [182], 
the loss of which significantly impairs heart mechanical 
function [183, 184]. The transmural distribution of myosin 
isoforms in the LV of large mammals has been suggested 
to play an important role in modulating the timing of force 
generation and relaxation across the ventricular wall by 
contributing to the twisting untwisting mechanism of LV 
contraction [43]. Increased expression of α-myosin in the 
epicardium may accelerate the rate of contraction such that 
shortening of the earlier-activated endocardial fibres is well 
coordinated with the later-activated epicardial fibres during 
systolic ejection. On the other hand, the maintained contrac-
tion state of the slow endocardial fibres during iso-volumic 
relaxation may enhance diastolic filling via stretching of the 
early relaxed epicardial fibres.
Another factor suggesting a role for the α-myosin in 
human heart is the observation that there is usually no 
detectable α-myosin protein in the LVs of failing human 
hearts e.g. [30]. Conversely, treatment of idiopathic DCM 
patients with β-blockers resulted in improved cardiac func-
tion associated with upregulation of expression of α-myosin 
[185]. In a related study, rat myocyte fragments express-
ing small amounts of α-myosin (~ 12%) had a much greater 
power output (+ 50%) than fragments lacking any α-myosin 
[129]. These observations suggest that small amounts of 
α-myosin in a background of β-myosin can have a dramatic 
effect on function. The presence of α-myosin could there-
fore result in both faster contraction and greater power of 
contraction.
This then leads back to questions about the role of small 
amounts of α-myosin in epicardial fibres in a working heart. 
In the case where mixed isoforms are present, then questions 
arise about the local distribution of isoforms in individual 
thick filament, in sarcomeres and between myocytes. Such 
questions are hard to address experimentally, but this is an 
area where modelling studies may provide a route to better 
understanding of such heterogeneity.
Heterogeneity in myosin dimers
In the review, thus far, we have considered the myosin as 
homodimers of α- or β-myosin HC. Yet, in smaller mam-
mals, there is considerable evidence that the αβ heterodimer 
exists. The three distinct myosin dimers were first discovered 
by running isolated cardiac myosin in non-denaturing elec-
trophoresis using pyrophosphate gels. The isoforms were 
referred to as V1 (αα), V2 (αβ) and V3 (ββ) [21] and later 
identified as the homo- and heterodimers via monoclonal 
antibodies [186]. There was a period of active research on 
the three dimers following their identification but little has 
been published in the last 10 years. The presence of the het-
erodimer is well established in rats, and guinea pigs where 
they can be as much as 25% of the total cardiac myosin [27], 
but there is no evidence of the heterodimers in the human 
heart or in other larger mammals. However, in the healthy 
human adult, there is only ~ 5% of α-myosin in the left ven-
tricle, so any heterodimer could only be present at very low 
levels. This may explain the lack of recent interest in the 
heterodimers but given that the 5% of α-myosin is confined 
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to small regions the local concentration of α may be much 
higher and the heterodimer could exist.
Since the myosin tails are 95% identical and the αα- and 
ββ-myosins must co-assemble in the sarcomere thick fila-
ments, it may not be a surprise that an αβ heterodimer can 
form [1]. However, there are no reports that the heterodimers 
can form spontaneously from mature αα and ββ homodi-
mers. Thus, when they form, the heterodimers are likely to 
assemble at the point of synthesis on the ribosome and, as 
for homodimers, probably involves specific chaperones dur-
ing assembly.
The potential of myosin heterodimer formation remains 
of interest not just for αβ dimers but for myosin mutations 
responsible for inherited myopathies, i.e. αα or ββ dimers 
where one chain carries a mutation. Most carriers of such 
mutations are heterozygous, so both wild-type myosin and 
myosin carrying the mutation will exist in a myocyte to vari-
able degree depending upon the expression levels of the two 
isoforms. Thus, the presence of myosin heterodimers is not 
only possible, but likely given that a mutation in the motor 
domain may not affect the stability of the dimer. No stud-
ies of cardiac myosin heterodimers have been reported for 
reasons outlined in the next section.
Experimentally, myosin heterodimers have been assem-
bled using smooth-muscle myosin [187] where the two iso-
forms were expressed in the insect cell expression system 
each carrying a distinct protein tag. This allowed the het-
erodimer to be separated from the two homodimers each 
of which only carried a single type of isolation tag. In this 
work, the primary interest was in the mechanism of regula-
tion of the 10s/6s switch in smooth-muscle myosin and the 
interaction between the two heads. A similar approach has 
been used to study tropomyosin heterodimers, both dimers 
of different isoforms and dimers carrying cardiomyopathy 
mutations [188, 189]. Here, the focus was on the effect of 
the interactions on the stability of the coiled coil. Similar 
questions arise about the coiled coil of the myosin tail and 
the packing of the tails into the thick filament where muta-
tions occur in the tail.
The cardiac myosin heterodimers are of interest in the 
study of cardiomyopathies where most carriers of myosin 
mutations are heterozygous. Is there a distinct behaviour 
of myosin carrying one vs. two mutations? Heterodimers 
are also a potentially useful experimental tool for several 
reasons. How do the two heads influence each other in the 
contraction cycle? Can a myosin with only one active head 
be assembled in a sarcomere? In the switched-off form of 
myosin, the two heads pack together to form the super-
relaxed state (SRX) with very low ATP turnover. A heter-
odimer would be useful to probe this head–head packing. 
Furthermore, many mutations associated with HCM are now 
thought to affect the stability of the SRX. Does this effect 
occur in a heterodimer or only in the homodimer?
Is there a difference between human type 1, slow 
skeletal muscle fibres and ventricle muscle fibres 
or myofibrils?
As outlined in Differences between atrium and ventricle con-
traction in addition to myosin isoforms, there are differences 
between ventricle and atrial myocytes and myofibrils beyond 
the myosin isoforms. The same is true of cardiac and slow 
skeletal muscle fibres which both express the same β-myosin 
isoform but differ in the expression of most other protein 
isoforms. In humans, biopsies from slow skeletal muscles 
are far simpler to obtain than from cardiac tissue. This had 
led to some investigators using soleus muscle biopsies to 
investigate the behaviour of muscle carrying β-myosin 
mutations associated with heart diseases [190–194]. With 
some surprise, however, early mechanical results obtained 
from soleus biopsies of patients carrying the first discovered 
HCM-associated mutation in β-myosin (the R403Q muta-
tion [193],) differed considerably from results obtained from 
ventricular samples of patients carrying the same mutation 
[195, 196]. Similarly, results from soleus biopsies of patients 
carrying mutations in the converter region of β-HC [191, 
194] differed from those observed in skinned cardiomyo-
cytes from the same patients [197], though, in this latter 
case, some specific cardiac remodelling associated with 
the disease had been identified as potential reasons for the 
reported differences. Differences between the properties of 
slow skeletal and ventricular β-myosin may, however, exist 
due to tissue specific post-translational modifications in the 
β-HC as reported several years ago in one investigation that, 
unfortunately, remained unfinished because of the untimely 
death of the first author [198]. Such differences could also 
explain possible variations in the impact of small molecules 
targeting the same myosin isoform in different tissues.
Conclusion
We set out to address the issue of how the two myosin iso-
forms found in human cardiac tissue are suited their distinct 
roles in cardiac ventricle vs. atria contraction. As presented, 
the data on isolated motor domains of myosin isoforms are 
consistent with the atrial α-isoform (HC + ELC) having a 
faster ATPase cycle and a faster velocity in a motility assay 
with a similar duty ratio. This is a result of a faster ADP 
release rate constant (controlling the lifetime of the attached 
state and velocity) balanced by a faster ATP hydrolysis step 
(controlling the lifetime of the detached state) maintaining 
the duty ratio. The data predict a faster contraction speed as 
observed in both myocytes and cardiac myofibrils express-
ing predominantly a single isoform. The higher velocity of 
the α-isoform means that it is predicted to generate more 
power (power = force x velocity) than β but at the expense of 
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greater use of ATP. The data on isolated motor domains also 
predict a change in the ATP economy, α burning more ATP 
per nm of travel, at maximum velocity and burning more 
ATP/sec when holding a high force. These myosin isoform 
properties are consistent with data from human myofibrils 
and skinned myocytes, as listed in Table 3, where the con-
tribution of EC coupling is removed. Here,  kACT ,  kTR,  Ca2+ 
activated ATPase and both slow and fast phases of relaxa-
tion are 3–five-fold faster for atrial sarcomeres, containing 
a majority of the α isoform, than ventricular sarcomeres 
with mostly β-myosin. These data are compatible with each 
mechanical parameter listed being influenced by the myosin 
isoform. In the intact electrically stimulated muscle, the rela-
tive roles of EC coupling and myosin isoforms are harder 
to disentangle, both contribute to the differences seen in a 
typical twitch contraction. This is most clearly seen in the 
mouse heart where atrial and ventricular twitches are quite 
distinct despite both containing near 100% α-myosin.
So, what is the role of the myosin isoform if EC coupling 
has a major role in defining the twitch characteristics? The 
large variability of β-myosin sequences between mammals 
of different sizes argues that the β isoform is tightly con-
strained and matches the needs of the heart (and slow mus-
cle) in a specific organism. The supportive role of α-myosin 
in the human atrium where its role is to assist refilling the 
ventricle, (requiring a higher speed of contraction but much 
less force and, therefore, a lower energy demand than the 
ventricle) is less constrained.
It is possible that the power that can be generated and the 
economy of ATP usage are the drivers of isoform diversity. 
Sarcomeric myosins are normally considered to contract 
most economically close to the maximum power output (in 
rat myocytes at 12 °C this is about 30% of  Po for α-myosin, 
20%  Po for β, there are no data for human myocytes or 
any mammal at 37 °C). But since the human atria actively 
contract only during its booster function and for a short 
period (50–100 ms at resting heart rate) against a relatively 
small blood pressure (well below 20 mmHg), it is likely 
that the human atrial cells do not contract near maximum 
power. In contrast, the human β-myosin actively contracts 
for ~ 3–400 ms in a resting heart, initially an iso-volumic 
contraction from 10 to 100 mmHg, for ~ 100 ms followed 
by 200–250 ms at a load of about 100 mmHg pressure as 
aortic valve opens and the blood is expelled from the ven-
tricle. It seems likely that the economy of ATP usage by the 
ventricle will be important and that the ventricle will oper-
ate near maximum power output. Power and efficiency data 
on human myocytes are difficult to obtain experimentally 
although there are data at 30 °C for Type 1 slow skeletal 
muscle fibres expressing β-myosin [199].
There remain many unresolved questions, as outlined in 
Outstanding problems, mostly to do with the lack of detailed 
information on the human atria/α-myosin vs. the more 
widely studied ventricle/β-myosin. Most of the outstanding 
questions are amenable to experimental study and we hope 
that this review may lead to the completion of the experi-
mental work required. Central among the missing infor-
mation are structures of the α-myosin and actin.α-myosin 
complexes, together with how a mixed population of α- and 
β-myosins combine mechanically in the human atrium and 
parts of the ventricle. Finally, we know that the regulation 
of the thick filament is different between fast skeletal and 
cardiac β-myosin/ventricle muscle [200, 201] but little is 
known about the thick filament regulation in atria/α-myosin.
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